Delving into the Latest Updates on ReGen Therapeutics Plc with Synapse

概览

关联

1

项与 ReGen Therapeutics Plc 相关的药物

Colostrinin(Ludwik Hirszfeld Institute Of Immunology & Experimental Therapy)

靶点-

作用机制-

在研机构-

原研机构

Ludwik Hirszfeld Institute Of Immunology & Experimental Therapy

在研适应症-

非在研适应症

阿尔茨海默症

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

1

项与 ReGen Therapeutics Plc 相关的临床试验

EUCTR2007-000083-24-GB / Not yet recruitingN/A

A survey of efficacy of zolpidem in patients with brain injury including SPECT brain scans in selected patients - zolpidem in brain damage

开始日期2007-06-07

申办/合作机构

ReGen Therapeutics Plc

100 项与 ReGen Therapeutics Plc 相关的临床结果

登录后查看更多信息

0 项与 ReGen Therapeutics Plc 相关的专利（医药）

登录后查看更多信息

2

项与 ReGen Therapeutics Plc 相关的文献（医药）

2004-02-01·The Protein Journal4区 · 生物学

The Alcohol-Induced Conformational Changes in Casein Micelles: A New Challenge for the Purification of Colostrinin

4区 · 生物学

Article

作者: Georgiades, Jerzy A. ; Bednarz, Renata ; Sokolowska, Agata ; Pacewicz, Magdalena ; Kruzel, Marian L. ; Wilusz, Tadeusz ; Polanowski, Antoni

Recent advances in protein separation technology have allowed for the isolation of whey proteins and peptides of significant biological importance. In this study, we report a novel method for isolation and purification of the neuroprotective proline-rich polypeptides, also known as Colostrinin (CLN). Although CLN was first isolated from ovine colostrum and characterized as a complex of small molecular peptides, its constituents are present also in other mammal colostrums. The previous purification protocols are very tedious, time consuming, and, due to the diverse characteristics of colostrum, also very difficult to validate. Thus, the aim of this study was to develop a simple protocol with a maximum recovery rate for CLN peptides. Here we demonstrate the two-step extraction/purification method that consists of methanol extraction and ammonium sulfate precipitation as the general principles. When compared with the original material, CLN obtained by this method shows (1) similar pattern of peptides in SDS PAGE, (2) identical amino acid analysis, characterized by high content of proline (22%), a high proportion of nonpolar amino acids, a low percentage of glycine, alanine, arginine, histidine, and no tryptophan, methionine, and cysteine residues, (3) similar pattern of HPLC profiles, and (4) its ability to induce IFN gamma and TNF alpha. More importantly, the protocol for the production of high-quality CLN can be accomplished in less than a 48 h timeframe. In addition, avoidance of excessively harsh conditions preserves the structure and biological activity of the peptides.

Journal of Molecular Neuroscience3区 · 医学

Modulation of 4HNE-Mediated Signaling by Proline-Rich Peptides from Ovine Colostrum

3区 · 医学

Article

作者: T. Kley Hughes ; Marian L. Kruzel ; Daniel Liebenthal ; Istvan Boldogh ; Terry L. Juelich ; G. John Stanton ; Jerzy A. Georgiades

In previous studies we showed that colostrinin (CLN), a complex of proline-rich polypeptides derived from ovine colostrum, induces mitogenic stimulation, as well as a variety of cytokines in human peripheral blood leukocytes, and possesses antioxidant activity in pheochromocytoma (PC12) cells. In this study we investigated the effects of CLN on 4-hydroxynonenal (4HNE)-mediated adduct formation, generation of reactive oxygen species (ROS), glutathione (GSH) metabolism, and the modification of signal transduction cascade that leads to activation of c-Jun N-terminal kinase (JNK) in PC12 cells. Here we demonstrate that CLN (1) reduced the abundance of 4HNE-protein adducts, as shown by fluorescent microscopy and Western blot analysis; (2) reduced intracellular levels of ROS, as shown by a decrease in 2',7'-dichlorodihydro-fluorescein-mediated fluorescence; (3) inhibited 4HNE-mediated GSH depletion, as determined fluorimetrically; and (4) inhibited 4HNE-induced activation of JNKs. Together, these findings suggest that CLN appears to down-regulate 4HNE-mediated lipid peroxidation and its product-induced signaling that otherwise may lead to pathological changes at the cellular and organ level. These findings also suggest further that CLN could be useful in the treatment of diseases such as Alzheimer's, as well as those in which ROS are implicated in pathogenesis.

100 项与 ReGen Therapeutics Plc 相关的药物交易

登录后查看更多信息

100 项与 ReGen Therapeutics Plc 相关的转化医学

登录后查看更多信息